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[Bu+Mel] combinations did not show synergistic cytotoxicity.
However, a combination of [0.25 mM Clo + 3.5 nM Gem]
resulted in about 60% inhibition of proliferation of p53-wild
type NCI H929 andMM.1R cells; combination indexes¼ 0.1e
0.6 suggested strong synergism. Two p53-mutated MM cell
lines, RPMI 8226 and U266B1, were more resistant to these
drugs. For example, exposure to [0.4 mM Clo+30 nM Gem]
inhibited proliferation of RPMI 8226 only by 25%. To deter-
mine if the cytotoxicity of [Clo+Gem] is mediated by p53,
H929 and MM.1R cells were pre-exposed to a p53-inhibitor,
piﬁthrin a. More than 50% of the [Clo+Gem]-mediated
cytotoxicity was reversed. The level of p53-regulated pro-
apoptotic PUMA and p21 proteins increased with [Clo+Gem]
but the effects were reversed in the presence of piﬁthrin a.
ATM kinasewas activated, further supporting involvement of
the ATM-p53 pathway in activation of DNA-damage
response. Phosphorylation of deoxycytidine kinase (DCK)
increased, and proteins involved in DNA-repair and rRNA
productionwere down-regulated. The activation of apoptosis
is suggested by the cleavage of PARP1 and caspases 3 and 8.
Further, mitochondrial membrane potential (MMP)
decreased in cells exposed to [Clo+Gem] consistent with
increased levels of proapoptotic factors cytochrome c, AIF
and SMAC/DIABLO in the cytosol, suggesting mitochondrial
leaks. These results show that the mechanism of synergistic
cytotoxicity of [Clo+Gem] in p53-positive MM cells involves
activated DCK, DNA-damage response, decreased MMP,
inhibited DNA repair, and nucleolar stress through decreased
rRNA. We are determining the effects of [Clo+Gem] in
primary cell samples from MM patients; the data will be
presented and discussed. Our investigation provides a basis
for introducing nucleoside analog combination(s) in both
cytoreductive induction therapy and pre-ASCT therapy in
MM, and in individualizing therapy based on p53 status to
avoid subjecting patients to ineffective therapy.255
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Background: Standard therapy for multiple myeloma (MM)
includes initial autologous hematopoietic cell trans-
plantation (autoHCT1) but this is not curative and most
patients will relapse. Data on salvage autoHCT2 or allogeneic
HCT (alloHCT2) are limited and the optimal salvage strategy
is unknown.
Methods: This is a retrospective study of MM patients >18
years of age who relapsed after autoHCT1 and underwent
salvage autoHCT2 or alloHCT2 between 1995-2011 at our
institution. Tandem auto-autoHCT or auto-alloHCT were
excluded.
Results: Characteristics of autoHCT2 (N¼27) and alloHCT2
(N¼19) patients were not signiﬁcantly different except the
alloHCT2 median age was signiﬁcantly (P ¼ .002) lower (54
years) than for autoHCT2 (62 years) and more alloHCT2
patients had KPS  70% (P ¼ .031). Complete and very good
partial remission (CR/VGPR) improved from 7% to 56% after
autoHCT2 and from 26% to 37% after alloHCT2. Of 15 patients
with progressive disease (PD) at the time of autoHCT2, 5achieved CR/VGPR and 7 PR. Nonrelapse mortality (NRM) at
3 years was 3.7% for autoHCT2 and 5.3% for alloHCT2 (P ¼
.901). Median progression free survival (PFS) and overall
survival (OS) for autoHCT2 (19 months, 23 months) and
alloHCT2 (6 months, 19 months) were not signiﬁcantly
different. For those entering salvage autoHCT2 in PD, PFS at
3-years was 41.7% (15.2-68.1%) and OS at 3-years was 45%
(16.1-73.9%). On multivariate analysis, time from autoHCT1
to relapse <1year vs. 1year (HR 24.81 [95% CI 2.4-249.9])
and no maintenance therapy vs. given after autoHCT2 (HR
12.19 [95% CI 2.5-249.9] impacted OS after autoHCT2.
However, only time from autoHCT1 to relapse<1 year versus
1 year (HR 18.55 [95% CI 2.28-150.57]) impacted PFS after
autoHCT2. For alloHCT2, no factors impacted NRM, PFS or OS.
For thosewith relapse from autoHCT1<1 year versus1 year
undergoing autoHCT2, median OS was 15 months (1-53) vs.
not yet reached at 143months andmedian PFS was 5months
(1-49) vs. not yet reached at 88 months. Major causes of
death for alloHCT2 were PD (n¼ 5), GVHD (n¼3), while for
autoHCT2, PD (n¼10), infection (n¼3).
Conclusions: Salvage autoHCT2 and alloHCT2 are both
feasible for patients with post autoHCT1MM relapse. Relpase
 1 year from autoHCT1 predicts for better PFS and OS in the
autoHCT2 group. Those with progressive disease can also be
salvaged by autoHCT2. Maintenance therapy after autoHCT2
is beneﬁcial and should routinely be used.256
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Background: High dose chemotherapy followed by autolo-
gous stem cell transplantation (ASCT) is effective therapy for
patients with POEMS syndrome. However, treatment before
ASCT has not been standardized. In addition, patients are at
high risk for an engraftment syndrome (ES) after ASCT, which
is associated with morbidity. Lenalidomide has recently
emerged as therapeutic options in patients with POEMS
syndrome. The purpose of the present study is to evaluate
the role of lenalidomide before ASCT.
Patients: Between December 2005 and May 2011, 7 patients
(pts) with POEMS syndrome underwent ASCT at our insti-
tution (median age at ASCT: 54 years, range: 36-66).
Peripheral blood stem cell (PBSC) was collected using
cyclophosphamide (CY) and granulocyte colony-stimulating
factor (G-CSF). PBSCwas used in 6 pts, whereas bonemarrow
and PBSC were used in a patient. Patients were conditioned
using melphalan (L-PAM; 200mg/sqm: n¼5, 140mg/sqm:
n¼1, 100 mg/sqm: n¼1).
Results: Of 7 pts, 5 have achieved neurologic improvement
after ASCT and are alive with a median follow-up of 44
months (range, 20-81 months), whereas 2 were not evalu-
ated for response because of early death. Interestingly, 2 pts
who had received prior therapy, lenalidomide (Case6: 15-
20mg per day for 53days, Case7: 15mg per day for 15days),
have been alive without ES after ASCT. However, of 5 pts who
had not received lenalidomide, 4 pts had ES after ASCT and
consequently 2 pts died (5 and 7 months).
